Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02247284
Other study ID # Glaucoma-Premium-OCT
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2015
Est. completion date December 31, 2019

Study information

Verified date March 2020
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess and compare the repeatability of SD-OCT (Spectralis™ OCT, Version 6.0, Heidelberg Engineering, Germany) RNFL thickness measurements with a new software (glaucoma premium module) with the well established peripapillary RNFL thickness measurements in patients with primary open angle glaucoma.


Description:

The purpose of this study is to assess and compare the repeatability of SD-OCT (Spectralis™ OCT, Version 6.0, Heidelberg Engineering, Germany) RNFL thickness measurements with the new software (method B) and with the previous method of measurement (method A) in patients with glaucoma.

It is a prospective, not blinded, not randomised, monocentric study. Inclusion of 50 patients with a diagnosis of primary open angle glaucoma (POAG), that will be recruited from the ophthalmology outpatient department of the UniversityHospital Zurich, Switzerland. All patients will undergo a full ophthalmic examination including measurement of refraction, best corrected visual acuity, examination of anterior and posterior compartment and measurement of the intraocular pressure. On the same day they will have 3 OCT examinations with a new method of measurement (method B).On the same day the first 10 patients will undergo also 3 OCT examinations with the previous method (method A) and they will get an other 3 OCT examinations with method B by a second observer. For this 10 patients the next consultation (3 months +/- 1 month) the 3 OCT examinations with method B will be repeated by the first observer.

Primary objectives are coefficient of variations (COV) of method A and B; Intra-class-correlations (ICC) of method A and B.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date December 31, 2019
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- diagnosis of POAG glaucoma

- male and female patients aged 18 years or older, no upper limit

- written informed consent

- visual acuity of more or equal to 0.5 Snellen

- refractive error between + /- 6.00 D spheric and under or equal than 2.00 D cylindrical

Exclusion Criteria:

- history of surgery other than uncomplicated cataract surgery

- disease affecting cornea, anterior compartment, lens, vitreous body

- history of severe ocular disease, particularly diseases affecting the optic nerve, other than glaucoma

- history of ocular trauma

Study Design


Intervention

Device:
RNFL and BMO-MRW SD-OCT
Masurement of peripapillary RNFL measurements with Heidelberg Spectralis SD-OCT (Heidelberg Engeneering GmbH, Heidelberg, Germany) old protocoll and in addition with the new Glaucoma Premium Module (software version 6.0) tocoll, which in addition to RNFL measurements include measurement of Bruch's Membrane Opening-based minimum rim width (BMO-MRW).

Locations

Country Name City State
Switzerland UniversityHospital Zurich Zurich ZH

Sponsors (1)

Lead Sponsor Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Retinal nerve fiber layer thickness (RNFL) Retinal nerve fiber layer thickness (RNFL) measured with Spectralis OCT baseline and 3 months +/- 1 month
Primary Bruch's membrane opening-based minimum rim width (BMO-MRW) Bruch's membrane opening-based minimum rim width (BMO-MRW) measured with Spectralis OCT baseline and 3 months +/- 1 month
Secondary Coefficient of variations (COV) of RNFL and BMO-MRW Coefficient of variations (COV) of RNFL and BMO-MRW baseline and 3 months +/- 1 month
Secondary Intra-class-correlations (ICC) of RNFL and BMO-MRW Intra-class-correlations (ICC) of RNFL and BMO-MRW baseline and 3 months +/- 1 month
See also
  Status Clinical Trial Phase
Recruiting NCT05564091 - Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma N/A
Recruiting NCT02792803 - A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma Phase 4
Terminated NCT02801617 - Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension Phase 3
Completed NCT01384149 - EXTERNAL SLT Treatment in Patients With Uncontrolled OPEN ANGLE GLAUCOMA Phase 1
Completed NCT00300079 - Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension Phase 4
Enrolling by invitation NCT00221923 - African Descent and Glaucoma Evaluation Study
Recruiting NCT05605743 - Alternate Nostril Breathing Training in Geriatrics With Glaucoma and High Blood Pressure N/A
Completed NCT04828057 - Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
Completed NCT01442896 - STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk
Enrolling by invitation NCT05557721 - Uddevalla Skövde Transscleral Micropulse Study
Recruiting NCT04595227 - Glaucoma Screening Using Dynamic Analysis of Computerized Pupillary Light Reflex Assessment Device
Terminated NCT04141865 - Effect of Xen Implantation on the Aqueous Humor Proteome
Completed NCT01979913 - An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More Phase 4
Completed NCT01943721 - A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension Phase 1
Completed NCT01769521 - Relationship Between 24-hour IOP Pattern and the 24-hour Blood Pressure Pattern in Patients With POAG N/A
Not yet recruiting NCT01711177 - Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma N/A
Completed NCT02023242 - Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes N/A
Recruiting NCT00773123 - Efficacy of Retinal Nerve Fiber Layer (RNFL) / Ganglion Cell Layer Thickness Ratio by RT-View Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma. N/A
Recruiting NCT00773877 - Comparison of Retinal Nerve Fiber Layer (RNFL) Thickness Measurements by Time-Domain and Spectral-Domain OCT In Glaucoma Patients N/A
Completed NCT02544646 - Changes in Ocular Rigidity After Trabeculectomy in Patients With POAG N/A